November 28, 2012

Intensive Deep-Dive into the Orphan Drug Act: Demystifying the Designation Process and Discovering the Accompanying Incentives

Overview

Washington, D.C., associate Keisha Hylton-Rodic will speak at the American Conference Institute’s Orphan Drugs and Rare Diseases Conference on Wednesday, Nov. 28, in Boston.

The forum is designed to give practitioners the complete picture of the orphan drugs and rare diseases landscape, including evolving laws, regulations, commercial implications, patent considerations, and the international framework.

As part of the pre-conference bootcamp, “Intensive Deep-Dive into the Orphan Drug Act: Demystifying the Designation Process and Discovering the Accompanying Incentives,” Keisha and other speakers will provide a nuanced look at the specifics of the statute and outline the complicated but rewarding process of using the statute and FDA framework to work towards a successful designation.  

For more information, click here.

 

 

Services and Industries

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.